Anaphylaxis

Aquestive Therapeutics plans to submit an NDA for Anaphylm in Q1 2025 based on topline results from the Oral Allergy Syndrome challenge study.

Early epinephrine intervention at home can potentially successfully treat anaphylaxis in children without further treatment in a hospital setting.

During situations in which those with severe allergies suffer from fatal anaphylaxis, adrenaline autoinjectors were shown in this study to have little effect on such reactions.

In the allergy news space, this Month in Review highlights some of the most significant stories covered by the editorial team.

The announcement follows July’s approval of the nasal spray, also known as neffy, for patients with Type 1 allergic reactions such as anaphylaxis.

These new data were announced by Aquestive Therapeutics and if approved, Anaphylm Sublingual Film could be the first orally-delivered, non-invasive severe allergy treatment.

In an announcement by Aquestive Therapeutics, these new findings demonstrated the potential of this orally-administered epinephrine treatment.

These findings may allow for patients with severe allergic reactions to have an alternative to epinephrine auto-injector devices.

These results provided valuable insights into occupational anaphylaxis through the use of anaphylaxis registry data.

The seismic shifts in mentality for allergy management and the strides made in immunotherapy have kept parents of children with allergies hopeful, but changes are still needed.

These newly-updated parameters were a response by the ACAAI and the AAAAI to recent evidence that had become visible.

The FDA's announcement requesting further study represents a step back in the process of 'neffy' becoming the first needle-free nasal spray epinephrine alternative.

This new research examined trends among adults with severe and recurrent anaphylaxis, and identified several major risk factors.

In phase 3 data presented at the AAAAI conference, an investigational intranasal epinephrine spray was found to have higher and more sustained pharmacokinetics than the standard reference product.

French researchers find that targeted allergy assessments may be needed in children with peanut allergies.

Dr. Epstein provides updates on a joint study between members of AAAAI and the American College of Allergy on the relationship between epinephrine and post-immunotherapy injection waiting periods.

Urticaria and angioedema with oral mucocutaneous involvement were commonly labeled as anaphylaxis upon presentation.

The proportion of anaphylaxis episodes was higher in the cohort of patients with peanut allergies, compared to a control group of patients with non-peanut food allergies.

Data pooled from 5 trials show a consistent and manageable safety profile for continued treatment with PALFORZIA.

Prior to the investigation, peanut allergy was often linked to high rates of anaphylaxis, with its prevalence in children and adolescents surpassing that found in adult patients.

Investigators believe the ALDORADO trial could properly diagnose the accuracy of open food challenges in comparison to the traditionally used double-blind placebo-controlled food challenge in pediatric patients with food allergies.

Investigators report that the small number of adverse events from the vaccine were successfully treated, with the remaining participants experiencing no allergic responses.

The investigative team in Canada found that pre-pregnancy weight may possibly influence a child’s risk of developing pediatric allergic diseases.

Investigators link early atopic manifestations and other complications to tree nut allergy, which account for most of all food related deaths by anaphylaxis.

Staff from schools across the United Kingdom express desire for enhanced staff preparedness and internal allergy policy review after being surveyed by investigators.

Post-survey responses show educators were eager to learn more about how to prevent students from experiencing food-anaphylactic reactions.

In data presented during AAAAI 21, researchers compared the 2006 and 2016 versions of the diagnostic criteria proposed by the NIAD/FAAN.

In the initial report, investigators find just 2.5 cases of anaphylaxis per million doses of the Moderna COVID-19 vaccine.

In nearly 1.9 million doses of the COVID-19 vaccine there has been only 21 total cases of anaphylaxis.

The rate of ED cases have decreased over years, yet proper patient follow-up is still lacking.